

## Disclaimer:

The views expressed are those of the presenter and do not reflect the official policy or position of the Defense Advanced Research Projects Agency (DARPA); the Office of the Assistant Secretary for Public Health Preparedness (ASPR) or United Therapeutics Corporation

Reference to any off-label use and reference to foreign-approved therapies will be identified.

Financial Conflict : United Therapeutics Corporation

# Why isn't TB included in Global Health Security Agenda

Metric	TB	COVID-19	Comment
BOD deaths/yr	1 M ( $\sigma$ )	4.7M (19 mo) <sup>1</sup>	endemicity threshold impossible to model for C19
CFR <small>1 1</small>	50% at 60 mo	.8 – 7 % <sup>2</sup>	Untreated <u>and</u> treated TB CFR far exceeds COVID
Cost (\$1000s)	19/ <b>152</b> /512	51-78 <sup>3</sup>	MDR TB cases 2X cost of high acuity COVID

<sup>1</sup> CFR <https://coronavirus.jhu.edu/data/mortality>

<sup>2</sup> Cost: ([https://wwwnc.cdc.gov/eid/article/20/5/13-1037\\_article](https://wwwnc.cdc.gov/eid/article/20/5/13-1037_article) )

<sup>3</sup> COVID <https://www.healthcarefinancenews.com/news/average-cost-hospital-care-covid-19-ranges-51000-78000-based-age>

# What New Innovation Can We Leverage for TB ?

	Model	Example
<b>MCM class</b>	<ul style="list-style-type: none"><li>• Gene encoded therapies</li><li>• PL -avid therapies</li><li>• Host modulating therapies</li></ul>	19 clinical; 2 market phase 9 clinical; 1 market phase multiple clinical ; 2 market
<b>Financial</b>	<ul style="list-style-type: none"><li>• Twinning (DARPA )</li><li>• NMI (HIV)</li><li>• TPPs for LMICs (HIV)</li></ul>	Dengue ---- HCV Metrics = productivity; self pay LMIC drugs adopted by rich countries
<b>Cooperative</b>	<ul style="list-style-type: none"><li>• RUA v. AMR</li><li>• Infrastructure</li></ul>	Rif and EPT (SS Africa)